Randy A Brown, M.D. - Research & Publications
Minimal Residual Disease By Either Flow Cytometry or Cytogenetics Prior to An Allogeneic Hematopoietic Stem Cell Transplant Is Associated With Poor Outcome in Acute Myeloid Leukemia
Blood Cancer Journal
Effect of Melphalan 140 Mg/M(2) Vs 200 Mg/M(2) on Toxicities and Outcomes in Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Transplantation-a Single Center Experience
A New Model to Predict Remission Status in Aml Patients Based on Day 14 Bone Marrow Biopsy
Peripheral Blood Cd34(+) Specific Donor Chimerism Analysis as An Early Indicator of Disease Relapse After Allogeneic Hematopoietic Stem Cell Transplant in Patients With Myelodysplastic Syndromes and Acute Myelogenous Leukemia.
A Phase I Study of the Vascular Disrupting Combretastatin, Oxi4503, in Patients With Relapsed and Refractory Acute Myeloid Leukemia (Aml) and Myelodysplastic Syndromes (Mds)
Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes.
Clinical Advances in Hematology and Oncology